Medtronic Acquires Lazarus Effect

You have to admit, naming a company Lazarus Effect sets up some big expectations. Medtronic plc (NYSE: MDT) had that in mind, no doubt, when it paid $100 million for medical device maker Lazarus Effect in late September. The target’s lead product is the Lazarus Cover™, which complements Medtronic’s Solitaire™ stent retriever platform. The technology is designed to address clinical needs with a novel nitinol “mesh cover” that folds over a stent retriever device during clot retrieval and wraps the stent with the clot inside. Medtronic will report the Lazarus Effect product line as part of its Neurovascular division within the Restorative Therapies Group.